Flipping Book

Treatment of limited stage follicular lymphoma with Rituximab

immunotherapy and involved field radiotherapy in a prospective

multicenter Phase II trial-MIR trial.

Witzens-Harig M, et al BMC cancer. 2011; 11: 87

• Trial aims at testing the combination's efficacy and safety n= 85 patients.

• Primary endpoint of the study is progression free survival.

• Secondary endpoints are :

• Response rate to Rituximab,

• Complete remission rate at week 18,

• Relapse rate,

• Relapse pattern,

• Relapse free survival,

• Overall survival,

• Toxicity

• Quality of life.